In covering Revolution Medicines (NASDAQ: RVMD ) I've grown more and more confident based on what I've seen, particularly coming out of the ASCO GI meeting this past January. I andI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s ...

Revolution Medicines (RVMD) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Ryan Asay - SVP & Corporate AffairsMark Goldsmith - CEO, President & ChairmanSteve Kelsey - President of Research & DevelopmentWei Lin - Chief Medical OfficerJack Anders - Chief Financial OfficerNone - ExecutiveJonathan Chang - Senior Managing DirectorClara Dong - Vice President - Biotechnology Equity Research Conference Call Participants Michael Schmidt - Senior Managing Director & Equity Research Analyst - Biot ...

Revolution Medicines (RVMD) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 Good day and thank you for standing by. Welcome to the Revolution Medicines Quarter one twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To wi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-39219 Securities registered pursuant to Section 12(b) of the Act: | | Trading Symbol(s) | | | --- | --- | --- | | Title o ...

Exhibit 99.1 Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress REDWOOD CITY, Calif., May 7, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS- addicted cancers, today announced its financial results for the quarter ended March 31, 2025, and provided an update on corporate progress. The company continues to make meaningful progress on its 2025 strategic ...

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2025, and provided an update on corporate progress. The company continues to make meaningful progress on its 2025 strategic priorities: Execute pivotal trials with daraxonrasib monotherapy in patients with previously treated metastatic ...

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and pr ...

Core Insights - Zoldonrasib, a RAS(ON) G12D-selective inhibitor, shows acceptable tolerability and promising initial antitumor activity in patients with KRAS G12D mutant non-small cell lung cancer (NSCLC) [1][2] Group 1: Clinical Data - New clinical data for zoldonrasib was presented at the American Association for Cancer Research (AACR) Annual Meeting, highlighting its potential as a treatment for NSCLC [1][2] - The Phase 1 study (RMC-9805-001) involved 90 solid tumor patients treated with 1200 mg once daily, demonstrating an acceptable safety profile consistent with previous data in pancreatic cancer [3] - The most common treatment-related adverse events (TRAEs) included nausea (39%), diarrhea (24%), vomiting (18%), and rash (12%), primarily Grade 1 or 2 in severity [3] Group 2: Efficacy Results - Preliminary antitumor activity was assessed in 18 efficacy-evaluable NSCLC patients, showing an objective response rate of 61% (11 patients) and a disease control rate of 89% (16 patients) [4] - The data indicates a high unmet need for new treatments in this patient population, as there are currently no approved targeted therapies for RAS G12D mutant cancers [5] Group 3: Company Overview - Revolution Medicines is focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes multiple RAS(ON) inhibitors [6] - The company is advancing zoldonrasib as a monotherapy and in combination therapies, aiming to provide innovative treatment options for hard-to-treat cancers [2][6]

Core Insights - Revolution Medicines, Inc. is set to present 11 oral and poster presentations at the AACR Annual Meeting in Chicago from April 25 – 30, 2025, focusing on targeted therapies for RAS-addicted cancers [1][7]. Oral Presentations - The first clinical data from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be presented in a late-breaking oral session on April 27, 2025 [2]. - The presentations include topics such as the preliminary safety and antitumor activity of zoldonrasib in KRAS G12D non-small cell lung cancer, and the discovery of RMC-5127, a RAS(ON) G12V-selective inhibitor [2]. Poster Presentations - Key poster presentations will cover early reductions in circulating tumor DNA (ctDNA) associated with clinical activity of daraxonrasib in RAS mutant non-small cell lung cancer, and mechanisms of resistance to daraxonrasib [3][4]. - Additional topics include the combination of RAS(ON) inhibitors to enhance immunotherapy efficacy in RAS-driven preclinical models [3]. Collaborator Presentations - Collaborator presentations will discuss distinct regulation of Cyclin D in colorectal cancer models and overcoming resistance to sotorasib through combination therapies [5][6]. - Other presentations will focus on long-term tumor control through combination therapy and preclinical evaluations of RMC-7977 for KRAS-mutant cholangiocarcinoma [5][6]. Company Overview - Revolution Medicines is a late-stage clinical oncology company developing targeted therapies for RAS-addicted cancers, with a pipeline that includes daraxonrasib, elironrasib, and zoldonrasib currently in clinical development [7]. - The company is also advancing RMC-5127, a RAS(ON) G12V-selective inhibitor, and exploring additional RAS(ON) mutant-selective inhibitors [7].

Core Insights - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [2] - The company is participating in two upcoming investor conferences, indicating active engagement with the investment community [1][3] Company Overview - Revolution Medicines specializes in RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [2] - The current R&D pipeline includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), all of which are in clinical development [2] - The company plans to advance RMC-5127, a RAS(ON) G12V-selective inhibitor, into clinical development next [2] - Additional pipeline opportunities include RMC-0708 (Q61H) and RMC-8839 (G13C), focusing on RAS(ON) mutant-selective inhibitors [2] Upcoming Events - The company will participate in the Needham 24 Annual Virtual Healthcare Conference on April 7 at 2:15 p.m. ET [3] - Additionally, Revolution Medicines will be part of the Stifel 2025 Virtual Targeted Oncology Forum on April 9 at 1:00 p.m. ET [3]